On Friday, Doximity hit an important performance benchmark, seeing its Relative Strength (RS) Rating jump into the 90-plus percentile with an improvement to 91, up from 88 the day before.
Looking For The Best Stocks To Buy And Watch? Start Here
IBD's unique RS Rating tracks technical performance by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research reveals that the market's biggest winners tend to have an RS Rating north of 80 as they launch their biggest climbs.
Doximity is not currently showing a potential buy point. See if the stock goes on to form a chart pattern that could kick off a new price move.
Doximity posted 52% EPS growth in the latest quarterly report, while sales growth came in at 17%.
Doximity earns the No. 4 rank among its peers in the Computer Software-Medical industry group. Veeva Systems Cl A is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
